Sanofi’s $15,000-a-Year Heart Drug May Trigger New Cost Concerns

Updated on

Is a Price War Coming for Cholesterol Drugs?

Sanofi and Regeneron Pharmaceuticals Inc. won U.S. approval for a powerful cholesterol-lowering drug that will sell for almost $15,000 a year, likely escalating a nationwide debate over the cost of medicine.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.